WaveMan
WaveMan · Company
ULS · Ul Solutions Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ULS UL Solutions (ULS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-testing laboratories · CIK 0001901440
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
234
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $633.1K priced

What the filings say about ULS

Insiders, 180 days
-$10.9M net sold
5 sellers · 14% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.3M
1 notice

UL Solutions insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, UL Solutions Inc. insiders sold a net $10.9M of stock across 64 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Scanlon Jennifer F.
President and CEO
SELL
2026-10-09 SECtraded 2026-10-08
12,500
$876.0K
+1.4%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (1 buy, 16 sales), the last on Sep 1, 2026.
  • The trade is 9.9% of the 126,724 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Scanlon Jennifer F. sold about $876.0K of ULS under a 10b5-1 plan on Oct 8, 2026; 234 funds added in the latest 13F quarter.
Scanlon Jennifer F.
President and CEO
SELL
2026-09-03 SECtraded 2026-09-01
10,495
$771.6K
-2.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (1 buy, 14 sales), the last on Aug 3, 2026.
  • The trade is 7.4% of the 141,229 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Scanlon Jennifer F. sold about $771.6K of ULS under a 10b5-1 plan on Sep 1, 2026; 234 funds added in the latest 13F quarter.
Scanlon Jennifer F.
President and CEO
SELL
2026-09-03 SECtraded 2026-09-01
2,005
$149.2K
-2.2%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (1 buy, 14 sales), the last on Aug 3, 2026.
  • The trade is 1.4% of the 139,224 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Scanlon Jennifer F. sold about $149.2K of ULS under a 10b5-1 plan on Sep 1, 2026; 234 funds added in the latest 13F quarter.
Scanlon Jennifer F.
President and CEO
SELL
2026-08-05 SECtraded 2026-08-03
3,629
$330.3K
-5.9%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (1 buy, 11 sales), the last on Jul 1, 2026.
  • The trade is 2.3% of the 160,595 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Scanlon Jennifer F. sold about $330.3K of ULS on Aug 3, 2026; 234 funds added in the latest 13F quarter.
Scanlon Jennifer F.
President and CEO
SELL
2026-08-05 SECtraded 2026-08-03
3,281
$301.5K
-5.9%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (1 buy, 11 sales), the last on Jul 1, 2026.
  • The trade is 2.1% of the 157,314 shares held after it.
  • No other insider sold within 30 days.
  • 234 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Scanlon Jennifer F. sold about $301.5K of ULS on Aug 3, 2026; 234 funds added in the latest 13F quarter.
64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 59 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$10.9M over 180 days
-$2.9M over 90 days
below 84% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
234 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+6.4% year over year
more than 55% of Pharma & Biotech
Margin
10.6% net margin
more than 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.2% of the float short (float per yahoo 2026-10-26) · 4.7 days to cover · settled 2026-09-30
What changed in the last 30 days
Oct 9President and CEO Scanlon Jennifer F. sold $876.0K under a 10b5-1 plan (Oct 8)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 8Director JENNIFER SCANLON filed to sell $2.3M by Oct 8 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ULS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-8.4%12M
-19%-2%+16%+33%2025-102025-122026-022026-042026-062026-082026-10 2025-12-05 · ULSE Inc. sold $975.0M2025-12-19 · ULSE Inc. sold $146.2M2026-06-02 · Schjotz Gitte sold $1.2M2026-06-03 · Schjotz Gitte sold $956.7K2026-10-08 · Scanlon Jennifer F. sold $876.0K2026-05-01 · Scanlon Jennifer F. sold $871.5K2026-05-07 · Schjotz Gitte sold $831.7K2026-09-01 · Scanlon Jennifer F. sold $771.6K2026-06-01 · Scanlon Jennifer F. sold $747.5K2026-04-01 · Scanlon Jennifer F. sold $650.4K2026-05-11 · Uggetti Alberto sold $610.0K2026-08-03 · Scanlon Jennifer F. sold $519.2K2026-06-01 · Scanlon Jennifer F. sold $502.4K2026-07-01 · Scanlon Jennifer F. sold $470.0K2026-04-01 · Scanlon Jennifer F. sold $418.4K2026-05-21 · Hecker Friedrich sold $408.2K2026-07-01 · Scanlon Jennifer F. sold $356.6K2026-08-03 · Scanlon Jennifer F. sold $330.3K2026-08-03 · Scanlon Jennifer F. sold $301.5K2026-05-01 · Scanlon Jennifer F. sold $273.1K2026-07-01 · Scanlon Jennifer F. sold $262.7K2026-05-28 · Uggetti Alberto sold $234.2K2026-09-01 · Scanlon Jennifer F. sold $149.2K2026-07-01 · Scanlon Jennifer F. sold $120.4K2026-06-09 · PEPPING KAREN K sold $70.9K2026-07-01 · Scanlon Jennifer F. sold $30.5K2025-12-08 · Genovesi John A bought $2.3K2025-12-08 · Hancock Lynn H bought $6232026-10-08 · JENNIFER SCANLON filed to sell $2.3M2026-07-01 · JENNIFER SCANLON filed to sell $3.8M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ULS: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
7,131,683 sh
$726.4M
Capital International Investors
6,115,196 sh
$622.9M
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
4,694,443 sh
$478.2M
VANGUARD CAPITAL MANAGEMENT LLC
3,504,948 sh
$357.0M
Capital Research Global Investors
3,367,530 sh
$343.0M

Congress trades in ULS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ULS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
JENNIFER SCANLON
Filed 2026-10-08
$2.3M
JENNIFER SCANLON
Filed 2026-07-01
$3.8M

ULS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus KAR Small-Mid Cap Core Fund
$55.7M position · as of 2026-06-30
5.1%
Wasatch Global Select Fund
$626.2K position · as of 2026-06-30
5.1%
Wasatch Long/Short Alpha Fund
$1.6M position · as of 2026-06-30
4.2%
Wasatch U.S. Select Fund
$675.8K position · as of 2026-06-30
4.0%
REYNDERS, MCVEIGH CORE EQUITY FUND
$4.2M position · as of 2026-07-31
3.9%
Ranger Small Cap Fund
$409.2K position · as of 2026-07-31
3.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Ms. Scanlon
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$15.3M
$56.5M
$3.3M
+129%
+26%
2024
$18.1M
$43.1M
$3.7M
+44%
+8%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $10.9M sold by insiders over 180 days, 234 funds added last quarter, $2.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ULS financials

Revenue growth
+6.4%
XBRL, annual
Net margin
10.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.1B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+16.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$436.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.19x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
2.25x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Return on equity
+37.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+16.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+32.0%
operating income after a 26.5% effective tax rate, over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+25.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
29.11x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
0.55x
P/E over trailing EPS growth of 53%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.1B$2.9B$2.7B$2.5B
Operating income$522.0M$462.0M$368.0M$412.0M
Net income$325.0M$326.0M$260.0M$293.0M
EPS (diluted)1.601.621.301.47
Operating cash flow$600.0M$524.0M$467.0M$372.0M
Cash$295.0M$298.0M$315.0Mn/a
Long-term debt$491.0M$692.0M$904.0Mn/a
Dividends paid$104.0M$100.0M$680.0M$1.6B
SEC XBRL, fiscal years, as known on 2026-10-28

ULS Stock Sonar score 6/7 axes

Find similar shapesCompare

ULS ranks highest on profitability (87th percentile) and financial health (71st), and lowest on insider conviction (7th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
87
Inputs
  • Return on equity+37.6% · 93 pct, sector of 545
  • Return on assets+16.7% · 91 pct, sector of 691
  • Return on invested capital+32.0% · 68 pct, sector of 45
  • Return on capital employed+25.5% · 96 pct, sector of 576
Financial health
71
Inputs
  • Debt to equity0.19x · 46 pct, sector of 352
  • Cash flow to debt2.25x · 95 pct, sector of 371
Growth
40
Inputs
  • Revenue growth, YoY+6.4% · 55 pct, sector of 505
  • Backlog growth, YoY-36.0% · 26 pct, sector of 40
Insider conviction
7
Inputs
  • Net Form 4 buying (codes P and S), 180d-$9.1M · 15 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
65
Inputs
  • Funds adding, latest quarter234 · 92 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$180K · 37 pct, sector of 133
Risk and compliance
50
Inputs
  • Short interest, % of float+7.2% · 49 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+10.4% · 51 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ULS filings, in plain words

Are UL Solutions insiders buying or selling ULS?

In the 180 days to 2026-10-28, UL Solutions insiders were net sellers, a net $10.9M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of ULS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $2.3M of stock; the latest, by JENNIFER SCANLON, was filed 2026-10-08.

Read the full summary

In the 180 days to 2026-10-28, UL Solutions insiders were net sellers of ULS, a net $10.9M across purchases and sales reported on Form 4 by 5 sellers. 14% of the 22 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $2.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies